Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Kaichao, Liu, Yang, Guo, Yelei, Qiu, Jingdan, Wu, Zhiqiang, Dai, Hanren, Yang, Qingming, Wang, Yao, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160389/
https://www.ncbi.nlm.nih.gov/pubmed/28710747
http://dx.doi.org/10.1007/s13238-017-0440-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160389/
https://www.ncbi.nlm.nih.gov/pubmed/28710747
http://dx.doi.org/10.1007/s13238-017-0440-4

Ejemplares similares